Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14846359 | 0.84 | ESR1 (0.50) | ESR1ESR2RAB9ASMN1; SMN2TSHR | |
| SCHEMBL5915148 | 0.81 | RAB9A (0.59) | RAB9AHPGDSMN1; SMN2TSHRNPC1 | |
| SCHEMBL1733770 | 0.72 | HPGD (0.47) | RAB9AHPGDSMN1; SMN2TSHRNPC1 | |
| Hydrazinecarboxamide SCHEMBL22471911 | 0.72 | RAB9A (0.45) | RAB9AHPGDSMN1; SMN2TSHRNPC1 | |
| SCHEMBL5640654 | 0.70 | NPC1 (0.73) | RAB9AHPGDSMN1; SMN2TSHRNPC1 | |
| SCHEMBL2969737 | 0.67 | ESR1 (1.00) | ESR1ESR2RAB9AHPGDNPC1 | |
| SCHEMBL36454 | 0.67 | ESR1 (1.00) | ESR1ESR2RAB9AHPGDNPC1 | |
| SCHEMBL12550898 | 0.67 | KDM4E (0.66) | RAB9AHPGDSMN1; SMN2NPC1TP53 | |
| SCHEMBL31043960 | 0.67 | RAB9A (0.49) | RAB9AHPGDSMN1; SMN2TSHRNPC1 | |
| SCHEMBL15256489 | 0.67 | ESR1 (0.46) | ESR1ESR2RAB9ANPC1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644377-A4 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | SUGEN INC (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7122548-B2 | Triazolotriazine compounds and uses thereof | SUGEN, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-7037909-B2 | Tetracyclic compounds as c-Met inhibitors | SUGEN, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1644377-A1 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050075340-A1 | Triazolotriazine compounds and uses thereof | SUGEN, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2005010005-A1 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | SUGEN, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005004808-A2 | TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20050014755-A1 | Tetracyclic compounds as c-Met inhibitors | SUGEN INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014755-A1 | Tetracyclic compounds as c-Met inhibitors | MET, RET, HGF | ESR1 1069/4885ESR2 341/4885RAB9A 921/4885 |
| US-20050075340-A1 | Triazolotriazine compounds and uses thereof | MET, TPMT, RET | ESR1 3133/4885ESR2 1287/4885RAB9A 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.